{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:15:55Z","timestamp":1788196555548,"version":"build-2803163510"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Beyond surgical intervention, hepatocellular carcinoma is mainly treated with 3 main approaches: transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) as local treatment, immune checkpoint inhibitors (ICIs), and tyrosine kinase inhibitors (TKIs). Up to now, clinical experts have not reached a consistent consensus on how to reasonably select combination therapy. Therefore, we performed this research to contrast the clinical outcomes of local treatment plus ICIs and TKIs (Local-ICIs-TKIs) with ICIs and TKIs, aiming to offer a practical reference basis for clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We searched the PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases on the computer, covering literature from their establishment to August 1st, 2025, for (Local-ICIs-TKIs) compared to ICIs and TKIs Clinical Investigation. The primary outcome indicators were treatment-related adverse events, median overall survival, median progression-free survival, objective response rate, and disease control rate. All statistical analyses were conducted using Stata 17 statistical software in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We screened 15 relevant pieces of literature, including 3208 patients. Compared with the ICIs-TKIs group, the Local-ICIs-TKIs treatment enhanced the pooled disease control rate (relative risk\u2005=\u20051.27; 95% confidence interval [CI]: 1.21\u20131.33) and objective response rate (relative risk\u2005=\u20051.87; 95% CI: 1.71\u20132.05). The combination therapy individually prolonged the median progression-free survival (hazard ratio\u2005=\u20050.59; 95% CI: 0.47\u20130.71) and median overall survival (hazard ratio\u2005=\u20050.48; 95% CI: 0.40\u20130.56). TACE and HAIC significantly elevated the risks of abdominal pain, anorexia, nausea, appetite loss, leukopenia, and liver injury. HAIC exhibited a higher incidence of abdominal pain, whereas TACE was more likely to lead to severe liver injury. The majority of adverse events were mild to moderate, and both interventions demonstrated favorable safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In comparison to the foundation of ICIs-TKIs systemic therapy, the addition of TACE or HAIC treatment exhibits good tolerability and can further yield superior clinical responses and prolong survival time for hepatocellular carcinoma patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049221","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:01:07Z","timestamp":1781600467000},"page":"e49221","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of local treatments combined with targeted therapy and immunotherapy versus targeted therapy plus immunotherapy alone in hepatocellular carcinoma: A meta-analysis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6043-4172","authenticated-orcid":false,"given":"Shaohua","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinbo","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4452-0320","authenticated-orcid":false,"given":"Tao","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260831","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260831","first-page":"17","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R3-20260831","doi-asserted-by":"crossref","first-page":"107313","DOI":"10.1016\/j.ejso.2023.107313","article-title":"Hepatocellular carcinoma.","volume":"50","author":"Dopazo","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"R4-20260831","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.3390\/cancers16132430","article-title":"Transarterial chemoembolization treatment paradigms for hepatocellular carcinoma.","volume":"16","author":"Fite","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R5-20260831","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.3748\/wjg.v21.i19.6018","article-title":"Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients.","volume":"21","author":"Ranieri","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R6-20260831","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.3390\/cancers14112798","article-title":"Emerging therapies for hepatocellular carcinoma (HCC).","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R7-20260831","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/liv.15504","article-title":"Immunotherapy in hepatocellular carcinoma: how does underlying liver disease influence therapeutic strategy and outcomes?","volume":"43","author":"Roth","year":"2023","journal-title":"Liver Int"},{"key":"R8-20260831","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R9-20260831","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2468-1253(23)00147-4","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice.","volume":"8","author":"Pinter","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R10-20260831","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma.","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"R11-20260831","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40261-024-01343-5","article-title":"Cost-effectiveness analysis of camrelizumab plus rivoceranib versus sorafenib as a first-line therapy for unresectable hepatocellular carcinoma in the Chinese health care system.","volume":"44","author":"Lang","year":"2024","journal-title":"Clin Drug Investig"},{"key":"R12-20260831","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial.","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R13-20260831","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1007\/s00330-023-09754-2","article-title":"Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.","volume":"33","author":"Jin","year":"2023","journal-title":"Eur Radiol"},{"key":"R14-20260831","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R15-20260831","first-page":"1711","article-title":"Is the Jadad score the proper evaluation of trials?","volume":"33","author":"Berger","year":"2006","journal-title":"J Rheumatol"},{"key":"R16-20260831","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/jgh.16463","article-title":"\u2013 combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.","volume":"39","author":"Diao","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"R17-20260831","doi-asserted-by":"crossref","first-page":"618206","DOI":"10.3389\/fonc.2021.618206","article-title":"Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma.","volume":"11","author":"Mei","year":"2021","journal-title":"Front Oncol"},{"key":"R18-20260831","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2147\/JHC.S417550","article-title":"Hepatic arterial infusion chemotherapy plus lenvatinib and tislelizumab with or without transhepatic arterial embolization for unresectable hepatocellular carcinoma with portal vein tumor thrombus and high tumor burden: a multicenter retrospective study.","volume":"10","author":"Chen","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"R19-20260831","doi-asserted-by":"crossref","first-page":"102622","DOI":"10.1016\/j.eclinm.2024.102622","article-title":"Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.","volume":"72","author":"Jin","year":"2024","journal-title":"EClinicalMedicine"},{"key":"R20-20260831","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00535-023-01976-x","article-title":"Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and PD-1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.","volume":"58","author":"Fu","year":"2023","journal-title":"J Gastroenterol"},{"key":"R21-20260831","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1097\/JS9.0000000000001378","article-title":"Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors.","volume":"110","author":"Guan","year":"2024","journal-title":"Int J Surg"},{"key":"R22-20260831","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1186\/s12885-021-08858-6","article-title":"Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"key":"R23-20260831","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.acra.2023.09.001","article-title":"Role of transarterial chemoembolization in the era of tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy for unresectable hepatocellular carcinoma: a retrospective propensity score matched analysis.","volume":"31","author":"Zhang","year":"2024","journal-title":"Acad Radiol"},{"key":"R24-20260831","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2147\/JHC.S386672","article-title":"Transarterial chemoembolization combined with immune checkpoint inhibitors plus tyrosine kinase inhibitors versus immune checkpoint inhibitors plus tyrosine kinase inhibitors for advanced hepatocellular carcinoma.","volume":"9","author":"Huang","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"R25-20260831","doi-asserted-by":"crossref","first-page":"15330338231166765","DOI":"10.1177\/15330338231166765","article-title":"Transarterial chemoembolization combined with PD-1 inhibitors plus lenvatinib showed improved efficacy for treatment of unresectable hepatocellular carcinoma compared with PD-1 inhibitors plus lenvatinib.","volume":"22","author":"Wang","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"R26-20260831","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00270-024-03724-x","article-title":"Transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors versus tyrosine kinase inhibitors plus immune checkpoint inhibitors in unresectable hepatocellular carcinoma with first- or lower-order portal vein tumor thrombosis.","volume":"47","author":"Zhang","year":"2024","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R27-20260831","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12072-023-10502-3","article-title":"Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.","volume":"17","author":"Xin","year":"2023","journal-title":"Hepatol Int"},{"key":"R28-20260831","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12885-024-12233-6","article-title":"HAIC combined with lenvatinib plus PD-1 versus lenvatinib plus PD-1 in patients with high-risk advanced HCC: a real-world study.","volume":"24","author":"Chang","year":"2024","journal-title":"BMC Cancer"},{"key":"R29-20260831","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12072-025-10884-6","article-title":"Hepatic arterial infusion chemotherapy combined with lenvatinib and programmed death receptor-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus: a multicenter, propensity score matching comparative study.","volume":"20","author":"Wu","year":"2026","journal-title":"Hepatol Int"},{"key":"R30-20260831","doi-asserted-by":"crossref","first-page":"176","DOI":"10.21037\/jgo-2025-33","article-title":"Real-world effectiveness and safety of TACE combined with lenvatinib plus immune checkpoint inhibitors in patients with BCLC-B stage hepatocellular carcinoma.","volume":"16","author":"Yao","year":"2025","journal-title":"J Gastrointest Oncol"},{"key":"R31-20260831","first-page":"105","article-title":"Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy.","volume":"4","author":"Xue","year":"2021","journal-title":"J Interv Med"},{"key":"R32-20260831","doi-asserted-by":"crossref","first-page":"709060","DOI":"10.3389\/fphar.2021.709060","article-title":"Comprehensive treatment of trans-arterial chemoembolization plus lenvatinib followed by camrelizumab for advanced hepatocellular carcinoma patients.","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"R33-20260831","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"R34-20260831","doi-asserted-by":"crossref","first-page":"1029951","DOI":"10.3389\/fonc.2022.1029951","article-title":"Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: a retrospective study.","volume":"12","author":"Han","year":"2022","journal-title":"Front Oncol"},{"key":"R35-20260831","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2147\/JHC.S332420","article-title":"Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study.","volume":"8","author":"Wu","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"R36-20260831","doi-asserted-by":"crossref","first-page":"982948","DOI":"10.3389\/fonc.2022.982948","article-title":"Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a two-center retrospective study.","volume":"12","author":"Sun","year":"2022","journal-title":"Front Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:00:16Z","timestamp":1788195616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":36,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049221","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"2024-11-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}